(IN BRIEF) Luxembourg has been selected to host the International Society of Geriatric Oncology Annual Conference in 2027, bringing a major global scientific meeting on cancer care for older adults to the Grand Duchy. The event will be organised under … Read the full press release
Posted in Business, Education, Healthcare, Luxembourg, Science
Tagged ACADI, Ageing Cancer and Disparities Research Unit, ageing populations, allied health professionals, cancer care, cancer research, Clinicians, conference infrastructure, Dr Sophie Pilleron, geriatric oncology, Grand Duchy, Healthcare Innovation, international partnerships, International Society of Geriatric Oncology, International Society of Geriatric Oncology Chooses Luxembourg for 2027 Annual Conference, Knowledge Exchange, LCB, LIH, Luxembourg, Luxembourg Convention Bureau, Luxembourg Institute of Health, Luxembourg Strengthens Medical Congress Profile With SIOG 2027 Hosting Win, medical community, medical congress, multidisciplinary collaboration, Older Adults, Public Institutions, researchers, scientific conference, SIOG, SIOG Annual Conference 2027, SIOG Annual Conference 2027 to Bring Global Geriatric Oncology Community to Luxembourg
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have developed WIN-DOSE, a proposed clinical-trial design to support more transparent and patient-centred selection of cancer drug doses in early-stage studies. The method enables researchers to establish a clear hierarchy … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged cancer drug development, cancer research, Cancer Research UK, Christina Yap, Clinical Cancer Research, clinical trial statistics, clinical trials, dose optimisation, dose selection, Drug Safety, early-stage clinical trials, Emily Alger, ICR, New Statistical Design Aims to Strengthen Evidence-Based Dose Decisions in Cancer Research, oncology, patient-centred research, patient-reported outcomes, Patient-Reported Outcomes Feature in New Framework for Selecting Cancer Drug Doses, pharmacodynamics, pharmacokinetics, precision medicine, The Institute of Cancer Research, treatment efficacy, treatment tolerability, United Kingdom, WIN-DOSE
(IN BRIEF) Scientists at The Institute of Cancer Research, London, and the University of Oxford have uncovered a mechanism that helps cancer cells survive radiotherapy by repairing radiation-induced DNA damage. The study found that insulin-like growth factor 1 receptor, or … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Balmus Laboratory, Blocking Cancer Cell Repair Pathway May Strengthen Future Radiotherapy Strategies, Cancer and Genome Instability Group, cancer cell survival, cancer research, Cancer Research UK, cancer therapy, cell survival mechanisms, chromatin, combination treatments, DNA damage response, DNA repair, DNA-dependent protein kinase catalytic subunit, DNA-PKcs, double-strand breaks, Dr Matthew Ellis, Dr Valentine Macaulay, drug targets, end-joining, genome instability, growth signalling, ICR, IGF-1R, insulin-like growth factor 1 receptor, Medical Research Council, Molecular Oncology, New Study Links Cancer Growth Receptor to DNA Repair After Radiation Treatment, non-homologous end joining, oncology, precision treatment, Professor Wojciech Niedzwiedz, prostate cancer, Prostate Cancer UK, radiation treatment, radiotherapy, Research Reveals How IGF-1R Helps Tumours Survive Radiation-Induced DNA Damage, resistant tumours, Targeting IGF-1R Could Make Cancer Cells More Vulnerable to Radiotherapy, The Institute of Cancer Research, treatment resistance, tumour biology, United Kingdom, University of Cambridge, University of Oxford
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have published a study in Trials showing that some UK cancer clinical trials may still include eligibility criteria that unintentionally restrict access for underserved patient groups. The study, conducted by … Read the full press release
Posted in Business, Education, Government, Healthcare, Law, Pharma & Biotech, Science, Society, Technology, United Kingdom
Tagged bladder cancer, cancer care, cancer clinical trials, cancer research, cancer treatment access, clinical research barriers, clinical trial eligibility criteria, clinical trial inclusion, Clinical Trials and Statistics Unit, Dr Georgiana Synesi, EDI, equality diversity and inclusion, geographical barriers, head and neck cancer, Health Research Authority, HIV exclusion criteria, ICR, ICR Study Identifies Persistent Barriers to Inclusive Participation in UK Cancer Clinical Trials, ICR-CTSU, INCLUDE Project, inclusive trial design, Institute of Cancer Research Review Highlights How Eligibility Criteria May Limit Access to Cancer Trials, Language Support, medical advances, Medicines and Healthcare products Regulatory Agency, MHRA, multi-centre randomised controlled trials, National Institute for Health and Care Research, New ICR Study Calls for More Inclusive Design of Bladder and Head and Neck Cancer Clinical Trials, NIHR-INCLUDE, oncology research, patient access, patient safety, people living with HIV, personalised cancer research, phase II trials, Phase III Trials, Professor Emma Hall, Rebecca Lewis, The Institute of Cancer Research, trial participation, Trials journal, UK cancer trials, underserved populations
(IN BRIEF) Researchers from the Luxembourg Institute of Health’s NORLUX Neuro-Oncology Laboratory have contributed to an international study published in Nature that sheds new light on how adult brain tumours, particularly IDH-mutant gliomas, evolve and become more aggressive after treatment. … Read the full press release
Posted in Artificial Intelligence (AI), Education, European Union, Healthcare, Luxembourg, Pharma & Biotech, Science, Technology
Tagged adult brain tumours, brain cancer, brain tumours, C20/BM/14646004/GLASSLUX, cancer cells, cancer research, chemotherapy, Department of Cancer Research, Dr Anna Golebiewska, FNR, genomic technologies, GLASSLUX, glioma recurrence, IDH inhibitors, IDH-mutant gliomas, immature cancer cells, INTER/TRANSCAN22/17612718/PLASTIG, international research consortium, LIH, LIH NORLUX Lab Contributes to Nature Study Advancing Understanding of Brain Tumour Evolution and Recurrence, LIH NORLUX Lab Contributes to Nature Study Revealing How Brain Tumours Become More Aggressive Over Time, longitudinal tumour samples, Luxembourg Institute of Health, Luxembourg National Research Fund, nature, Nature Study with LIH NORLUX Contribution Identifies Biological Pathways Driving Brain Tumour Progression, neuro-oncology, NORLUX Lab Contributes Rare Patient Samples and Preclinical Models to Major Study on Glioma Recurrence, NORLUX Neuro-Oncology Laboratory, patient-derived preclinical models, personalised treatment, PLASTIG, PRECISION-PDX cohort, radiotherapy, single-cell technologies, therapy resistance, tumour environment, tumour evolution, tumour progression
(IN BRIEF) The University of Warwick-coordinated OPTIMA trial, sponsored by University College London, has found that the Prosigna genomic test could help many patients with early-stage hormone-sensitive breast cancer avoid unnecessary chemotherapy without compromising outcomes. The trial followed more than … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged Adrienne Morgan, American Society of Clinical Oncology, ASCO Annual Meeting, breast cancer, breast oncology, cancer recurrence, cancer research, Cardiff, chemotherapy, clinical trial, early stage breast cancer, gene test, genomic test, hormone therapy, hormone-sensitive breast cancer, Independent Cancer Patients’ Voice, Karen Bonham, lymph nodes, Major OPTIMA Trial Results Could Support Wider NHS Use of Genomic Testing to Reduce Chemotherapy Overtreatment, National Institute for Health and Care Research, NHS, NHS laboratories, Nice, NIHR, OPTIMA trial, Patient and Public Involvement, patient outcomes, personalised treatment, Professor Janet Dunn, Professor Rob Stein, Prosigna, radiotherapy, treatment decision-making, tumour biology, UCL, UCL Cancer Institute, University College London, University of Warwick, University of Warwick and UCL-Led Breast Cancer Trial Highlights Potential to Spare Thousands from Chemotherapy, University of Warwick-Coordinated OPTIMA Trial Shows Genomic Test Could Help Breast Cancer Patients Avoid Unnecessary Chemotherapy, unnecessary chemotherapy, Veracyte Inc, Warwick Clinical Trials Unit
(IN BRIEF) The Institute of Cancer Research, London, has presented encouraging results from the phase Ib/II OrigAMI-4 clinical trial, showing that the targeted immunotherapy drug amivantamab shrank tumours in 42 per cent of patients with recurrent and/or metastatic head and … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged American Society of Clinical Oncology, amivantamab, Amivantamab Demonstrates Encouraging Survival and Tumour Shrinkage Outcomes in Hard-to-Treat Head and Neck Cancer Patients, ASCO Annual Meeting, bispecific monoclonal antibody, cancer research, Carl Walsh, clinical trial, complete response, EGFR, head and neck squamous cell carcinoma, HNSCC, ICR, immunotherapy, Johnson & Johnson, Met, metastatic head and neck cancer, oncology, OrigAMI-4, OrigAMI-5, outpatient cancer treatment, partial response, phase Ib II trial, Phase III Trial, platinum-based chemotherapy, Professor Kevin Harrington, Professor Kristian Helin, recurrent head and neck cancer, Subcutaneous Injection, targeted cancer treatment, Targeted Immunotherapy Injection Shows Strong Clinical Activity in Patients with Treatment-Resistant Head and Neck Cancer, The Institute of Cancer Research and Royal Marsden Team Advance Clinical Evidence for Injectable Head and Neck Cancer Treatment, The Institute of Cancer Research London, The Royal Marsden NHS Foundation Trust, treatment-resistant cancer, tumour shrinkage
(IN BRIEF) Scientists at The Institute of Cancer Research in London have uncovered new details about how the CDK11 enzyme is activated and regulated, providing insights that could support future cancer drug development. Using cryo-electron microscopy, the team mapped the … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Amy McGeoch, Breakthrough Research Maps Active CDK11 Complex and Its Role in Gene Expression and RNA Splicing, cancer cell growth, cancer research, Cancer Therapies, CDK11, cell division, cellular biology, cryo-electron microscopy, Cryo-EM, cyclin L, cyclin-dependent kinase, Dr Basil Greber, drug development, enzyme regulation, gene expression, gene transcription, ICR, London, Medical Research Council, Molecular Biology, Nature Communications, New Findings from London Researchers Advance Understanding of Cellular Enzyme Involved in Cancer Growth, oncology research, protein complex, pseudo-substrate, RNA splicing, SAP30BP, Scientists Uncover Structural Secrets of CDK11 That Could Support Future Cancer Drug Development, spliceosome, structural biology, The Institute of Cancer Research, therapeutic research
(IN BRIEF) AB Volvo has announced the winners of the 2026 Assar Gabrielsson Foundation Prize, recognising achievements in both basic and clinical cancer research. Ketan Thombare received the award in the basic science category for his research into RNA modifications … Read the full press release
Posted in Automotive, Awards, Business, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, Science, Sweden, Technology
Tagged AB Volvo, AB Volvo Announces 2026 Assar Gabrielsson Foundation Prize Winners Recognising Advances in Cancer Research, Assar Gabrielsson Foundation, basic science research, biomarkers, cancer research, clinical research, Ella Äng Eklund, Eva Forssell Aronsson, glioma, Ketan Thombare, KRAS mutation, Leading Cancer Researchers Honoured with 2026 Assar Gabrielsson Foundation Awards by AB Volvo, Louise Carstam, lung cancer, Neuroblastoma, Sahlgrenska Academy, University of Gothenburg
(IN BRIEF) Empa and HOCH Health Ostschweiz have launched a research project to develop nanozyme-based therapies for treating aggressive brain tumors such as astrocytoma, using near-infrared light to activate the treatment directly at the tumor site. The approach aims to … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology
Tagged astrocytoma, blood-brain barrier, brain tumors, cancer research, Empa, Empa and HOCH Health Ostschweiz Explore Innovative Nanotherapy to Improve Brain Cancer Outcomes, Giacomo Reina, Hedy Glor Meyer Foundation, HOCH Health Ostschweiz, Isabel Hostettler, nanomedicine, nanozymes, Near Infrared Activated Nanozymes Offer New Hope for Precision Brain Tumor Treatment, near infrared light therapy, oncology innovation, Swiss Cancer Foundation, targeted therapy
(IN BRIEF) Novartis has agreed to acquire SNV4818 from Synnovation Therapeutics, a next-generation PI3Kα inhibitor designed to selectively target mutations in HR+/HER2- breast cancer. The therapy, currently in Phase 1/2 clinical trials, aims to improve treatment tolerability by focusing on … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged Breast Cancer Treatment, cancer research, clinical trials Phase 1/2, HR positive HER2 negative, Novartis, Novartis Strengthens Breast Cancer Portfolio with Acquisition of Next Generation Selective PI3Kα Therapy, oncology pipeline, pharmaceutical acquisition, PI3Kα inhibitor, PIK3CA mutation, Pikavation Therapeutics, precision medicine, SNV4818, solid tumors, Synnovation Therapeutics, targeted therapy
(IN BRIEF) A review published in Nature Reviews Neurology highlights how researchers at the Luxembourg Institute of Health, in collaboration with the University of Luxembourg, are advancing brain tumour research through the development of organoid models. These three-dimensional, patient-derived structures … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Investment, Luxembourg, Management, Marketing, Pharma & Biotech, Science, Technology
Tagged Anna Golebiewska, brain tumours, cancer research, drug screening, Luxembourg Institute of Health, Luxembourg Institute of Health Researchers Outline New Advances in Organoid-Based Brain Cancer Research and Drug Screening, Luxembourg Institute of Health Showcases Organoids as a Promising Tool for Personalised Brain Tumour Treatment Strategies, molecular profiling, Nature Reviews Neurology, neuro-oncology, NORLUX Neuro-Oncology Laboratory, organoids, patient-derived models, personalised treatment, precision medicine, tumour heterogeneity, University of Luxembourg
(IN BRIEF) The Institute of Cancer Research, London has appointed Dr Michelle Harrison to its Board of Trustees, bringing extensive experience in global public policy, corporate leadership, and charity governance to the organisation’s governing body. A former Chief Executive and … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Science, Technology, United Kingdom
Tagged Big Win Philanthropy, Board of Trustees, Campaign for Science and Engineering, cancer research, charity governance, corporate governance, Dr Michelle Harrison, Dr Michelle Harrison Joins Board of Trustees at The Institute of Cancer Research, ICR, ICR Brings Senior Public Policy and Business Expert onto Board of Trustees, INNOVATION, Involve, leadership, London, Nesta, Professor Dame Julia Buckingham, Public Affairs, public policy, Reykjavik Global Forum, Social Finance UK, STRATEGY, The Institute of Cancer Research London, Verian Group, WPP Group
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have uncovered how the DNA repair enzyme XPF-ERCC1 is recruited to sites of damage and activated inside cells, resolving a long-standing question in molecular biology and providing structural insights that … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI in science, AlphaFold, Basil Greber, cancer research, cryogenic electron microscopy, DNA damage, DNA repair, genome integrity, ICR, Institute of Cancer Research, Medical Research Council, Molecular Biology, Nature Communications, New Structural Insights into XPF-ERCC1 Could Help Refine Future Cancer Treatments, SLX4, structural biology, XPF-ERCC1
(IN BRIEF) The Institute of Cancer Research has welcomed Sutton Council’s approval of ambitious plans led by Aviva Capital Partners and Socius to create around one million square feet of new life-sciences research and laboratory space across a 12-acre site … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Insurance, Investment, Management, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Aviva Capital Partners, cancer research, Daniel May, economic growth, high-skilled jobs, ICR, ICR Welcomes Approval of New One-Million-Square-Foot Life-Sciences Campus at The London Cancer Hub, Innovation Gateway, Institute of Cancer Research, Kristian Helin, laboratory space, life sciences, London Borough of Sutton, research and development, science infrastructure, Socius, Sophie White, Sutton, The London Cancer Hub, The Royal Marsden NHS Foundation Trust
(IN BRIEF) Researchers at the Luxembourg Institute of Health have published a major review in Nature Cancer proposing a new framework to explain and potentially overcome the long-standing resistance of glioblastoma to immunotherapy. The study analyses how this aggressive brain … Read the full press release
Posted in Education, Healthcare, Industrial, Luxembourg, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged brain cancer, cancer immunology, cancer research, Department of Cancer Research, glioblastoma, immune plasticity, immune resistance, immunotherapy, LIH, Luxembourg Institute of Health, Nature Cancer, Nature Cancer Review Reveals Why Immunotherapy Fails in Glioblastoma and How to Rethink Treatment, neuro-oncology, NORLUX Neuro-Oncology Laboratory, NORLUX Scientists Propose Immune Microenvironment Framework for Next-Generation Glioblastoma Therapies, oncology innovation, T cells, tumour microenvironment, tumour-associated macrophages
(IN BRIEF) Researchers at the University of Southampton have developed a new antibody design that boosts the immune system’s ability to fight cancer by enhancing activation of T cells through the CD27 receptor. Published in Nature Communications, the study shows … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Science, Technology, United Kingdom
Tagged antibody engineering, Cancer Immunotherapy, cancer research, Cancer Research UK, CD27, Centre for Cancer Immunology, immune system, Nature Communications, T cells, University of Southampton, University of Southampton Advances Next-Generation Immunotherapy by Amplifying T Cell Activation
(IN BRIEF) ZEISS has launched its labs@location program in Australia, naming the Walter and Eliza Hall Institute of Medical Research’s Centre for Dynamic Imaging as its first local partner. The collaboration brings ZEISS’ advanced microscopy technologies together with WEHI’s long-standing … Read the full press release
Posted in Business, Electronics & Machinery, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Technology
Tagged advanced imaging, Australia research collaboration, biomedical research, cancer research, Centre for Dynamic Imaging, Disease Research, Dr René Hessling, imaging workflows, infection and immunity, labs@location, lifelong health, microscopy innovation, Professor Kelly Rogers OAM, research infrastructure, scientific collaboration, Walter and Eliza Hall Institute of Medical Research, WEHI, ZEISS, ZEISS Australia and New Zealand, ZEISS Expands Global labs@location Network to Australia Through WEHI Collaboration
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have achieved a breakthrough in the treatment of advanced sarcoma and melanoma through a novel combination of isolated limb perfusion (ILP) and oncolytic virus therapy. In the first clinical trial … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Amgen Pharmaceuticals, cancer research, clinical trial, Dr Lucy Bull Foundation, ICR, ILP, immunotherapy, isolated limb perfusion, Journal for ImmunoTherapy of Cancer, London, Mabs Mardulyn Charitable Foundation, melanoma, NIHR Biomedical Research Centre, oncolytic virus, Professor Alan Melcher, Professor Andrew Hayes, Robert McAlpine Foundation, Royal Marsden Melanoma and Sarcoma Research Fund, sarcoma, Sarcoma UK, T-VEC, talimogene laherparepvec, The Institute of Cancer Research, The Institute of Cancer Research pioneers new dual treatment combining virus therapy and isolated limb perfusion to enhance immune response in advanced cancer, The Royal Marsden NHS Foundation Trust, tumour immunity, United Kingdom, virotherapy
(IN BRIEF) GSK announced that its B7-H3-targeted antibody-drug conjugate GSK5764227 (GSK’227) has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of pulmonary neuroendocrine carcinoma, including small-cell lung cancer (SCLC). The designation is supported … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, ARTEMIS-001, B7-H3, breakthrough therapy designation, cancer research, EMA, EMA Grants Orphan Drug Designation to GSK’s B7-H3 Antibody-Drug Conjugate for Pulmonary Neuroendocrine Carcinoma, FDA, GSK, GSK Strengthens Oncology Pipeline With EMA Orphan Drug Status for GSK’227 in Small-Cell Lung Cancer, GSK5764227, GSK’227, immuno-oncology, lung cancer, NEC, ODD, oncology, oncology pipeline, orphan drug designation, PRIME designation, pulmonary neuroendocrine carcinoma, relapsed or refractory, SCLC, Small cell lung cancer, solid tumours, targeted therapy
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?